Spoken Alpha
BIO
BIO-RAD LABORATORIES, INC.
Overview
Bio-Rad Laboratories manufactures and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics.
BIO-RAD LABORATORIES, INC is a Healthcare company operating in Medical Devices with a $9.95B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0116 Q&A exchanges
- Q4 FY2025Earnings2026-02-126 Q&A exchanges
- Q3 FY2025Earnings2025-10-2915 Q&A exchanges
- Q2 FY2025Earnings2025-07-3120 Q&A exchanges
- Q1 FY2025Earnings2025-05-0126 Q&A exchanges
- Q4 FY2024Earnings2025-02-1329 Q&A exchanges
- Q3 FY2024Earnings2024-10-3021 Q&A exchanges
- Q2 FY2024Earnings2024-08-0117 Q&A exchanges
- Q1 FY2024Earnings2024-05-0711 Q&A exchanges
- Q4 FY2023Earnings2024-02-1515 Q&A exchanges
- Q3 FY2023Earnings2023-10-2618 Q&A exchanges
- Q2 FY2023Earnings2023-08-0323 Q&A exchanges
- Q1 FY2023Earnings2023-05-0413 Q&A exchanges
- Q4 FY2022Earnings2023-02-1617 Q&A exchanges
- Q3 FY2022Earnings2022-10-2718 Q&A exchanges
- Q2 FY2022Earnings2022-07-2815 Q&A exchanges
- Q1 FY2022Earnings2022-04-2816 Q&A exchanges
- Q4 FY2021Earnings2022-02-1016 Q&A exchanges
- Q3 FY2021Earnings2021-10-2819 Q&A exchanges
- Q2 FY2021Earnings2021-07-2919 Q&A exchanges
- Q1 FY2021Earnings2021-04-3023 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-03EPS— vs $2.61—Rev— vs ——EODHD
- Q2 FY20262026-08-03EPS$2.62 vs $2.34+12.0%Rev$651.0M vs ——EODHD
- Q1 FY20262026-04-29EPS$1.89 vs $1.99-5.0%Rev$592.1M vs ——EODHD
- Q4 FY20252026-02-11EPS$2.51 vs $2.70-7.0%Rev$693.2M vs ——EODHD
- Q3 FY20252025-10-28EPS$2.26 vs $1.93+17.1%Rev$653.0M vs ——EODHD
- Q2 FY20252025-07-30EPS$2.61 vs $1.75+49.1%Rev$651.6M vs ——EODHD
- Q1 FY20252025-04-30EPS$2.54 vs $1.78+42.7%Rev$585.4M vs ——EODHD
- Q4 FY20242025-02-12EPS$2.90 vs $2.88+0.7%Rev$667.5M vs ——EODHD
- Q3 FY20242024-10-29EPS$2.01 vs $1.18+70.3%Rev$649.7M vs ——EODHD
- Q2 FY20242024-07-31EPS$3.11 vs $2.02+54.0%Rev$638.5M vs ——EODHD
- Q1 FY20242024-05-06EPS$2.29 vs $2.14+7.0%Rev$610.8M vs ——EODHD
- Q4 FY20232024-02-14EPS$3.10 vs $2.87+8.0%Rev$681.2M vs ——EODHD
- Q3 FY20232023-10-25EPS$2.33 vs $2.81-17.1%Rev$632.1M vs ——EODHD
- Q2 FY20232023-08-02EPS$3.00 vs $2.68+11.9%Rev$681.1M vs ——EODHD
- Q1 FY20232023-05-03EPS$3.34 vs $3.48-4.0%Rev$676.8M vs ——EODHD
- Q4 FY20222023-02-15EPS$3.31 vs $3.44-3.8%Rev$730.3M vs ——EODHD
- Q3 FY20222022-10-26EPS$2.60 vs $2.77-6.1%Rev$680.8M vs ——EODHD
- Q2 FY20222022-07-27EPS$3.38 vs $2.77+22.0%Rev$691.1M vs ——EODHD
- Q1 FY20222022-04-27EPS$4.94 vs $3.23+52.9%Rev$700.1M vs ——EODHD
- Q4 FY20212022-02-09EPS$3.21 vs $2.87+11.8%Rev$732.8M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $2.61 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-03 | $2.62 | $2.34 | +12.0% | $651.0M | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $1.89 | $1.99 | -5.0% | $592.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-11 | $2.51 | $2.70 | -7.0% | $693.2M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $2.26 | $1.93 | +17.1% | $653.0M | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $2.61 | $1.75 | +49.1% | $651.6M | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $2.54 | $1.78 | +42.7% | $585.4M | — | — | EODHD |
| Q4 FY2024 | 2025-02-12 | $2.90 | $2.88 | +0.7% | $667.5M | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $2.01 | $1.18 | +70.3% | $649.7M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $3.11 | $2.02 | +54.0% | $638.5M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $2.29 | $2.14 | +7.0% | $610.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $3.10 | $2.87 | +8.0% | $681.2M | — | — | EODHD |
| Q3 FY2023 | 2023-10-25 | $2.33 | $2.81 | -17.1% | $632.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $3.00 | $2.68 | +11.9% | $681.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $3.34 | $3.48 | -4.0% | $676.8M | — | — | EODHD |
| Q4 FY2022 | 2023-02-15 | $3.31 | $3.44 | -3.8% | $730.3M | — | — | EODHD |
| Q3 FY2022 | 2022-10-26 | $2.60 | $2.77 | -6.1% | $680.8M | — | — | EODHD |
| Q2 FY2022 | 2022-07-27 | $3.38 | $2.77 | +22.0% | $691.1M | — | — | EODHD |
| Q1 FY2022 | 2022-04-27 | $4.94 | $3.23 | +52.9% | $700.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-09 | $3.21 | $2.87 | +11.8% | $732.8M | — | — | EODHD |
Source: EODHD. BIO reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Norman D SchwartzCEO2 yr 2 mo20 callsCurrent
- Roop Kalyan LakkarajuCFO2 yr 7 mo9 callsCurrent
- Jonathan P DivincenzoCOO2 yr 2 mo4 callsCurrent
- Rajat MehtaEVP, GBL Commercial Operations1 yr 3 mono recorded callsCurrent
- Eva Anette EngelhardtEVP, President, CDG2 yr 5 mono recorded callsCurrent
- James R BarryEVP, President, LSG2 yr 6 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BIO.
$ curl https://api.spokenalpha.com/v1/companies/BIOFAQ
Frequently asked about BIO
Where can I find BIO-RAD LABORATORIES, INC.'s (BIO) earnings call transcripts?
Spoken Alpha indexes BIO's earnings call transcripts at https://spokenalpha.com/companies/BIO. Each call links to attributed speakers and parsed analyst Q&A. BIO-RAD LABORATORIES, INC.'s own investor relations page is at https://investors.bio-rad.com/overview/default.aspx.
When was BIO-RAD LABORATORIES, INC.'s most recent earnings call?
BIO-RAD LABORATORIES, INC. (BIO) held its most recent earnings call on 2026-05-01, covering fiscal Q1 2026.
What sector is BIO in?
BIO-RAD LABORATORIES, INC. (BIO) operates in the Healthcare sector (Medical Devices industry).